Track F

F2 Latest Trends in Cell-, Gene- and Regenerative Medicine-based Commercialization

Track: Licensing Successful Practices

Target Audience: Intermediate

Mark Taylor, University Health Network

Patrick Bedford, Centre for Commercialization of Regenerative Medicine
Stefan Koehler, University of Michigan
Shawn Singh, Vistagen Therapeutics Inc.

The recent growth in the number of cell-, gene- and regenerative medicine-based deals is once again showing that opportunities lie in this area for technology transfer offices (TTOs). Products are entering trials, and early successes are emerging, further fueling the importance of research, development and investment in this space. A deeper understanding of the commercialization landscape is key to maximizing these opportunities for TTOs. In this session, we’ll explore the latest trends and experiences in the licensing of these technologies and their further development, trials and eventual productization. In particular, a focus will be on identifying and sharing opportunities where TTOs can participate, in addition to straight licensing activities.

Return to Schedule

AUTM 2018 Annual Meeting Sponsors